Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Oligoprogressive 1

Interventions

pembrolizumab 168Carboplatin 137Cisplatin 85Paclitaxel 81Gemcitabine 79Pemetrexed 75Bevacizumab 65Docetaxel 56Fluorouracil 50Oxaliplatin 49Dexamethasone 47durvalumab 43atezolizumab 40Leucovorin 40130-nm albumin-bound paclitaxel 40Capecitabine 38Cetuximab 36Rituximab 35Nivolumab 35Fulvestrant 35Cyclophosphamide 34Injections 31venetoclax 29Lenalidomide 29Prednisone 28enzalutamide 27Letrozole 26pomalidomide 25Irinotecan 25daratumumab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × DEAE-Dextran × 30 days × Clear all
NCT05846659 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
16 enrolled 13 charts

Oligoprogressive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡